RetinaCME
VIDEOCMEABO MOC

Diabetic Macular Edema Management in 2021: What’s New?

Author(s)/Faculty: Jorge A. Fortun, MD; Nancy M. Holekamp, MD; Yasha Modi, MD
Release Date: 6/18/2021Expiration Date: 6/17/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: VideoProvider:
Although anti-VEGF therapy has revolutionized the management of diabetic macular edema (DME), it is also has its shortcomings. Many patients do not respond to treatment with these agents, and many more are undertreated due to practical difficulties that surface with the need for frequent therapy and assessment. Clinicians need to consider other existing therapies when anti-VEGF fails, and to be aware of the evidence for their use either alone or in combination with anti-VEGF, to increase efficacy while reducing the frequency of treatment. Corticosteroid implants have been shown to have the potential to improve visual outcomes in DME. However, ophthalmologists continue to have limited knowledge of the use of these agents. In this continuing education activity, expert clinicians discuss the latest updates regarding corticosteroids in DME, as well as some challenging cases.